Physician profile
Kiran P Maski
NPI 1598945024
$105,158.12
in general payments reported to CMS, 2019-2025
8 companies · $44K in 2025
The $44K reported for 2025 was more than what 98% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.50 · 2020: $2,600 · 2021: $14K · 2022: $6,600 · 2023: $12K · 2024: $26K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $78K · Travel and Lodging: $1,968 · Food and Beverage: $1,793 · Education: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $77,861.50 |
| Travel and Lodging | $1,968.20 |
| Food and Beverage | $1,793.42 |
| Education | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $40,116.93 | 2020-2025 | Lybalvi |
| Jazz Pharmaceuticals INC. | $33,270.62 | 2019-2025 | |
| Harmony Biosciences LLC | $15,957.00 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,897.65 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $5,220.00 | 2024-2025 | Quviviq, Quviviq |
| Eisai INC. | $2,160.00 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $1,335.92 | 2024 | Lumryz |
| Vertex Pharmaceuticals Incorporated | $200.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Maski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.